INFY.NS Infosys Limited NSE pre-market 26 Mar 2026: AI deal boosts outlook

INFY.NS stock opens pre-market at INR 1,279.10 after Infosys Limited confirmed a $465.00 million acquisition of Optimum Healthcare IT. The deal strengthens Infosys’s healthcare and AI service mix and is visible in pre-market flows with volume at 10,824,030.00 shares. Investors will watch the April earnings date and AI revenue traction as the immediate catalysts for trading activity on the NSE.

INFY.NS stock: Pre-market snapshot and news drivers

Infosys Limited (INFY.NS) shows an open of INR 1,270.00 and previous close INR 1,278.30 with intraday range INR 1,257.10–1,290.60. The company announced the Optimum Healthcare IT buy for $465.00 million today, a move that expands its healthcare SaaS and AI services. Reuters reported the acquisition and deal terms source.

INFY.NS stock: AI strategy, products and competitive edge

Infosys leverages Infosys Nia and the Edge product suite to capture AI-led transformation in healthcare and finance. The Optimum deal complements its existing platforms such as Finacle and Wingspan. Analysts view this as a strategic fit given rising enterprise AI budgets, potentially lifting AI service revenue growth above the company-wide revenue growth of 3.85% reported for FY 2025.

INFY.NS stock: Fundamentals, valuation and cash flow

At INR 1,279.10, Infosys trades at PE 17.74 with EPS 72.10 and dividend yield 3.52%. Key ratios show strong liquidity with current ratio 1.81 and debt to equity 0.11. Free cash flow yield is 6.88% and return on equity is 29.68%, indicating healthy cash conversion and shareholder returns. Price/Book stands at 6.12, reflecting premium valuation versus some peers.

INFY.NS stock: Technicals, volume and trading signals

Technicals show RSI 41.09 and ADX 38.08, signalling a strong trend but neutral momentum. Bollinger middle band sits at INR 1,279.97 with ATR 40.06, so expected daily moves are near INR 40.06. On-balance volume is negative while average volume is 11,221,460.00, close to today’s 10,824,030.00, suggesting normal liquidity conditions for active institutional trading.

Meyka AI rates INFY.NS with a score out of 100 and forecast

Meyka AI rates INFY.NS with a score out of 100: 82.04 | Grade: A | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12‑month price of INR 1,733.54, implying an upside of 35.56% from INR 1,279.10. Forecasts are model-based projections and not guarantees. For company filings and further market context, see Investing.com coverage source and the Meyka INFY.NS page Meyka INFY.NS page.

Final Thoughts

Key takeaways for INFY.NS stock in pre-market trade on 26 Mar 2026: Infosys is expanding its AI and healthcare footprint with a $465.00 million acquisition. The stock trades at INR 1,279.10 with a PE of 17.74 and EPS 72.10, offering a dividend yield of 3.52% and strong cash flow metrics. Technicals show neutral momentum but steady institutional liquidity. Meyka AI’s forecast model projects INR 1,733.54 over the next 12 months, implying a 35.56% upside versus the current price. These forecasts are model-based projections and not guarantees. Investors focused on AI stocks should weigh the acquisition’s integration risks, near-term margin impact, and the upcoming earnings on 16 Apr 2026, before adjusting exposure on the NSE.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.